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A B S T R A C T
Background: Sepsis is a dysregulated host response to infection. The aim of this study was to investigate the
effects of complement- and CD14 inhibition on phagocytosis of live and dead Gram-negative and Gram-positive
bacteria in human whole blood.
Methods: Lepirudin-anticoagulated blood was incubated with live or dead E. coli or S. aureus at 37 °C for 120min
with or without the C5aR1 antagonist PMX53 and/or anti-CD14. Granulocyte and monocyte phagocytosis were
measured by flow cytometry, and five plasma cytokines by multiplex, yielding a total of 28 mediators of in-
flammation tested for.
Results: 16/28 conditions were reduced by PMX53, 7/28 by anti-CD14, and 24/28 by combined PMX53 and
CD14 inhibition. The effect of complement inhibition was quantitatively more pronounced, in particular for the
responses to S. aureus. The effect of anti-CD14 was modest, except for a marked reduction in INF-β. The re-
sponses to live and dead S. aureus were equally inhibited, whereas the responses to live E. coli were inhibited less
than those to dead E. coli.
Conclusion: C5aR1 inhibited phagocytosis-induced inflammation by live and dead E. coli and S. aureus. CD14
blockade potentiated the effect of C5aR1 blockade, thus attenuating inflammation.
1. Introduction
It is crucial to mount an adequate and proportionate innate immune
response towards invading pathogens that pose a threat to the human
host (Medzhitov, 2008). The complement system and the toll-like re-
ceptors (TLRs) expressed on a plethora of cells, leukocytes in particular,
constitute a first line of defence against microbes and other immediate
dangers (Beutler, 2004; Matzinger, 2002). Usually, their sensing of
danger and prompt activation results in a swift and harmless resolution
of the initial threat. However, innate immunity is sometimes over-
whelmed by pathogens and their numerous pathogen-associated
molecular patterns (PAMPs) leading to dysregulated inflammation, as
seen in sepsis (Brown et al., 2006; Ward and Gao, 2009). In this regard,
early prevention of an overwhelming innate immune response may be a
key to reduce associated morbidity and mortality (Dellinger et al.,
2013).
By inhibiting key bottleneck molecules of the complement system,
such as C5, and CD14 of the TLR system, we aim to reduce an otherwise
detrimental, downstream inflammatory response (Mollnes et al., 2008).
This inhibition has successfully reduced the otherwise great in-
flammatory responses to both unimicrobial (Escherichia coli, Neisseria
meningitidis and Staphylococcus aureus) and polymicrobial threats in
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human whole blood and porcine models of sepsis (Barratt-Due et al.,
2013; Skjeflo et al., 2014, 2015; Hellerud et al., 2017; Mollnes et al.,
2002). Hitherto, the combined regimen has not been tested for pha-
gocytosis over time, nor on a possibly different inflammatory response
induced by dead compared to live bacteria.
Likewise, systematic comparison of live and dead bacteria has rarely
been performed. We argue that this is an important issue for two main
reasons. First, the CFU counts in patients only represent a fraction of the
total amount of bacteria identified in patients by qPCR, as qPCR counts
both live and dead bacteria. Here we intended to compare the potency
of live and killed bacteria to induce a broad innate immunity based
inflammatory response. Secondly, in vitro experiments are frequently
made with killed bacteria for several reasons, e.g. to keep control with
the number of bacteria during the experiment, or for safety reasons.
Thus, it is of importance to investigate whether dead bacteria reflect the
same responses as live bacteria under experimental conditions.
We hypothesize that inhibiting overwhelming phagocytosis of both
live and dead Gram-positive and Gram-negative bacteria, with sub-
sequent reductions in the levels of inflammatory mediators including
cytokines and reactive oxygen species (ROS), can contribute to reduced
inflammation in sepsis, and ultimately could be beneficial to patients
concurrently treated with antibiotics.
2. Materials and methods
2.1. Whole blood model of bacteremia
Whole blood experiments were performed using single whole blood
samples for all assays from 6 healthy donors and carried out as pre-
viously described (Mollnes et al., 2002). In brief, blood drawn by ve-
nipuncture was immediately distributed into polypropylene tubes
containing Dulbecco’s phosphate-buffered saline, PBS (Sigma-Aldrich,
St Louis, MO), inhibitors or controls. The samples were preincubated
for 10min at 37 °C. After preincubation, PBS with CaCl2 and MgCl2
(Sigma-Aldrich, St Louis, MO), dead, i.e. heat-inactivated at 60 °C for
60min, or live, Alexa-labelled Staphylococcus aureus (S. aureus) strains
Cowan 1 (ATCC; American Type Culture Collection, Manassas, VA;
12598) or Alexa-labelled Escherichia coli (E. coli, strain LE392, ATCC
33572) were added to a final whole blood concentration of 1×108/mL
and 1×107/mL, respectively. Each donor signed an informed consent
form before participation and the regional ethics committee of the
Northern Norway Regional Health Authority approved the study.
The time zero (T0) sample was processed immediately after blood
sampling. After 60, 90, 120 and 240min of incubation at 37°C, blood
was transferred to tubes containing ethylenediamine tetraacetic acid
(EDTA, 10mM), spun down at 3220× g at 4°C for 15min for plasma
separation, and the plasma frozen for later cytokine analysis.
Furthermore, the phagocytosis of Alexa-labelled bacteria in whole
blood was assessed after 15, 45, 90 and 120min. Separate experiments
with the same donors were carried out where live S. aureus was titrated,
108/mL-107/mL-106/mL. Blood incubation was as described above. At
time points zero, 60 and 120min, blood was transferred to poly-
propylene tubes for analysis of phagocytosis. At time point zero and
120min, blood was transferred to a multitier plate for PI staining and to
DMEM/F-12 (Life Technologies, Paisley, UK) for colony forming units
(CFU) quantification. Flow cytometric analysis on these experiments
were performed on a NovoCyte (Acea, San Diego, Ca).
All equipment, tips and working solutions were endotoxin-free.
Polypropylene tubes (4.5 mL; Nunc, Roskilde, Denmark) with lepirudin
(Refludan®; Celgene, Uxbridge, UK; 50mg/L) were used as antic-
oagulant.
2.2. Inhibitors and antagonists
The recombinant anti-human CD14 IgG2/4 hybrid monoclonal an-
tibody (r18D11) was produced as previously described (Lau et al.,
2013) and added at a final concentration of 10 μg/mL. The cyclic
hexapeptide PMX53 (sequence Ace-Phe-[Orn-Pro-dCha-Trp-Arg])
blocking the C5a receptor 1 (C5aR1) was synthesized and purified as
previously described (Croker et al., 2016), and used at a final con-
centration of 10 μM. Each inhibitor has been carefully titrated in our
laboratory to give maximum blockade and established, fixed doses were
therefore used.
2.3. Alexa-labelling of bacteria
For Alexa-labelling, the bacteria were washed, and the supernatant
was discarded. Afterward, NaHCO3 (0.2M, 600 μL, pH 8.35, sterile-
filtered and heat-inactivated 1 h at 60 °C) was added together with 6 μL
of Alexa FLUOR® 488 carboxylic acid succinimidyl ester (10 g/L) in
DMSO. The tube was packed in tinfoil and was rotated for 1 h at am-
bient temperature. Bacteria were washed additional three times with
PBS and centrifuged for 5min at 8000× g before resuspension in PBS.
The bacteria were counted in Truecount tubes (Becton-Dickinson, San
José, CA) using a LSRII flow cytometer with FACSDiva software
(Becton-Dickinson).
2.4. Cytokine-assay
EDTA-plasma was prepared by centrifugation, as described above.
The cytokine levels in the plasma were analyzed using the microsphere-
based Bio-Plex Human Cytokine 4-plex Assay (Bio-Rad, Hercules, CA).
The assay was performed according to instructions from the manu-
facturer and comprised the following: Interleukin (IL-) 1β, IL-6, IL-8
and tumor necrosis factor (TNF). Concentrations of IFN-β were de-
termined with the VeriKine-HS human IFN-β serum ELISA kit (PBL
Assay Science, Piscataway, NJ).
2.5. Phagocytosis assay
Whole blood samples were transferred to polypropylene tubes
stored on ice, containing an equal amount of quenching solution (from
the Phagotest kit, Glycotope Biotechnology GmbH, Heidelberg,
Germany) to stop further phagocytosis and to quench the fluorescence
of surface-bound but not phagocytosed bacteria. Next, washing solution
(Phagotest, Glycotope Biotechnology) was added and the tubes were
spun down at 300× g for 5min. The supernatant was discarded before
a second wash. The cells were then stained with anti-CD14 PE and anti-
CD45 PerCp (both Becton-Dickinson) for 15min before adding the
lysing buffer (Phagotest, Glycotope Biotechnology). The lysing buffer
was left to act for 20min at ambient temperature before the cells were
spun down at 300× g for 5min. The supernatant was discarded and the
cells were washed once more, PBS was added and the samples were
transferred to a 96-well polypropylene storage plate (Falcon, Corning
Inc., NY) for flow cytometry. Threshold was set on forward scatter and
PMNs and monocytes were gated for by using a CD14/side scatter dot
plot on CD45 positive events. The mean fluorescence intensity (MFI) of
the Alexa fluorochrome was used as a measure for phagocytosis. An
example of the gating strategy and its corresponding histogram is
shown in the Supplementary Fig. 1A.
2.6. PI-staining
For the monocyte viability study, 70 μL of whole blood was mixed
with 2 μL of EDTA at time point zero or after 120min of incubation.
10 μL of this was incubated with 2 μL anti-CD45 PE and 2 μL anti-CD14
APC for 15min on ice and then stained with 236 μL PBS PI (1,3 μg/mL).
Threshold was set at CD45 PE and monocytes were gated for in APC/
SSC plot. Dead cells were positive events in the 675/30 nm filter.
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2.7. Statistics and data presentation
The data were analyzed with GraphPad Prism 6.0 h and 7.0c
(GraphPad Software, San Diego, CA). In accordance with the paper of
Matthews and colleagues concerning analysis of serial measurements in
medical research (Matthews et al., 1990), we summarized total re-
sponses as areas under the curve. Normality was then tested for using
the Kolmogorov–Smirnov test and any non-normal or skewed (skew-
ness≥ ±1) data was log-transformed before testing by one-way re-
peated measures ANOVA and Dunnet’s post hoc test comparing all
columns with that of stimulated, uninhibited whole blood. P values<
0.05 were considered significant and all graphs and tables show means
with 95% confidence intervals (CI).
3. Results
3.1. Granulocyte phagocytosis of E. coli: effect of, time, single-inhibition
and viability (Fig. 1)
Firstly, the E. coli induced a significant (P < 0.05) increase in the
phagocytic activity in granulocytes compared to PBS alone (Fig. 1).
Secondly, this activity was significantly (P < 0.05) reduced at all time-
points for both inhibitors and their combination. Notably, the effect of
anti-CD14 increased markedly from 15 to 45min whereas the effect of
PMX53 was consistently strong at all time-points. The effects were si-
milar for dead (Fig. 1, upper panels) and live (Fig. 1, lower panels)
bacteria. The relative level of phagocytosis was reduced by single in-
hibition of C5aR1 and CD14 at all time-points, both in response to live
and dead bacteria. The corresponding data for Fig. 1 with absolute
values for MFI are shown in the Supplementary Fig. 2.
3.2. Monocyte phagocytosis of E. coli: effect of time, single-inhibition and
viability (Fig. 2)
The E. coli induced a significant (P < 0.05) increase in the pha-
gocytic activity in monocytes compared to PBS alone (Fig. 2). C5aR1
inhibition significantly reduced the phagocytosis of the dead bacteria
throughout the whole experiment (Fig. 2, upper panels), and the pha-
gocytosis of the live bacteria at 15 and 45min (Fig. 2, lower panels). In
contrast to the phagocytosis in granulocytes, there were no effect of
inhibiting CD14 alone on the phagocytosis in monocytes of neither live
nor dead bacteria (Fig. 2).
3.3. Effect of combined inhibition of C5aR1 and CD14 on the monocyte and
granulocyte phagocytosis of E. coli
The data above describes the effects of single inhibition of C5aR1
and CD14. Notably, he combination of PMX53 and anti-CD14 reduced
the phagocytosis of both live and dead bacteria by both granulocytes
and monocytes at all time-points (15, 45, 90 and 120min), i.e. in all 16
cases (Figs. 1 and 2).
3.4. Granulocyte phagocytosis of S. aureus: effect of single-inhibition, time
and viability (Fig. 3)
Firstly, the S. aureus induced a significant (P < 0.05) increase in
the phagocytic activity in granulocytes compared to PBS alone (Fig. 3).
Secondly, this activity was significantly (P < 0.05) reduced at all time-
points in response to both live and dead bacteria when using PMX53
alone. In contrast, single inhibition of CD14 had no effect.
3.5. Monocyte phagocytosis of S. aureus: effect of single-inhibition, time
and viability (Fig. 4)
Firstly, the S. aureus induced a significant (P < 0.05) increase in
the phagocytic activity in monocytes compared to PBS alone (Fig. 4).
Secondly, this activity was significantly (P < 0.05) reduced at all time-
points but 120min in response to dead bacteria (Fig. 4, upper panels)
when using PMX53 alone, and at 15 and 45min for the live bacteria
(Fig. 4, lower panels). At 120min, there were insufficient monocytes for
adequate analysis. As for the phagocytosis in granulocytes, CD14 in-
hibition had no effect (Fig. 4).
3.6. Effect of combined inhibition of C5aR1 and CD14 on the granulocyte
and monocyte phagocytosis of S. aureus
As described above, anti-CD14 exerted no inhibitory effect on the
phagocytosis of S. aureus when used alone, yet the level of phagocytosis
in monocytes at 45 min for PMX53-treated samples was reduced further
when combining PMX53 with anti-CD14 (Fig. 4). This was the case both
for dead and live bacteria. In contrast to E. coli, the single inhibition of
C5aR1 was the main reason for the reduced level of phagocytosis in 16
Fig. 1. Effects of C5a receptor 1 (C5aR1)
blockade and CD14 inhibition on the granulo-
cyte phagocytosis of live and dead E. coli.
The relative inhibition of the phagocytosis of
dead (top panels) and live (bottom panels)
when using the C5aR1 antagonist PMX53 (la-
belled PMX), a neutralizing anti-CD14 antibody
(labelled aCD14) or the combination thereof
(PMX+ aCD14) was analyzed at 15, 45, 90
and 120min. * P < 0.05, analyzed using re-
peated measures, two-way ANOVA with
Dunnet’s multiple comparisons post-hoc test,
comparing all columns with the second re-
ference column in black.
E.W. Skjeflo, et al. Molecular Immunology 112 (2019) 131–139
133
Fig. 2. Effects of C5a receptor 1 (C5aR1) blockade and CD14 inhibition on the monocyte phagocytosis of live and dead E. coli.
The relative inhibition of the phagocytosis of dead (top panels) and live (bottom panels) E. coli when using the C5aR1 antagonist PMX53 (labelled PMX), a
neutralizing anti-CD14 antibody (labelled aCD14) or the combination thereof (PMX+aCD14) was analyzed at 15, 45, 90 and 120min. * P < 0.05, analyzed using
repeated measures, two-way ANOVA with Dunnet’s multiple comparisons post-hoc test, comparing all columns with the second reference column in black.
Fig. 3. Effects of C5a receptor 1 (C5aR1) blockade and CD14 inhibition on the granulocyte phagocytosis of live and dead S. aureus.
The relative inhibition of the phagocytosis of dead (top panels) and live (bottom panels) S. aureus when using the C5aR1 antagonist PMX53 (labelled PMX), a
neutralizing anti-CD14 antibody (labelled aCD14) or the combination thereof (PMX+aCD14) was analyzed at 15, 45, 90 and 120min. * P < 0.05, analyzed using
repeated measures, two-way ANOVA with Dunnet’s multiple comparisons post-hoc test, comparing all columns with the second reference column in black.
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out of 16 cases studied.
3.7. Effect of staphylococcal concentration on phagocytosis
Live S. aureus was incubated with whole blood for 120min at final
concentrations of 1× 108/mL, 1× 107/mL and 1×106/mL. The level
of phagocytosis was assessed at 60 and 120min. All three concentra-
tions induced phagocytosis at both time points in both granulocytes
(Fig. 5) and monocytes (Fig. 6). The phagocytic response was dose-
dependent with increasing amounts of bacteria (note that different
scales were needed on the y-axis). PMX-53 alone reduced the level of
phagocytosis at all time points for all concentrations except for
1× 108/mL at 120min in monocytes, whereas combined PMX-53 and
anti-CD14 reduced phagocytosis at all time-points in response to all
concentrations.
3.8. Total levels of phagocytosis and cytokine release as area under the
response-time curve
Due to the time-dependent differences we observed at single time
points, we summarized the total effect of single and combined inhibi-
tion on the total phagocytosis and cytokine release throughout the ex-
periment. The % reduction is shown for both live and dead E. coli (Table
I) as well as for S. aureus (Table 2). The corresponding absolute data are
shown in Supplementary Tables I and II. Because the dead bacteria
were more heavily stained with the Alexa dye, these supplementary
tables indicate a higher ingestion of dead than live bacteria. In the
Supplementary Fig. 1B we have therefore adjusted for the difference in
staining, illustrating comparable levels of phagocytosis in granulocytes
and monocytes for both live and dead E. coli.
E. coli. PMX alone reduced total phagocytosis for both cell types and
both viabilities (Table 1). The IL-8-response was the only one of the five
cytokines measured that was reduced for both live and dead bacteria
(Table 1). Single CD14 inhibition reduced granulocyte but not mono-
cyte phagocytosis. IFN-β levels were markedly reduced for both live
(68%) and dead (78%) bacteria, whilst the IL-6-response was only re-
duced for dead bacteria (Table 1). However, the combination of PMX53
and CD14 substantially reduced the levels of all seven cases for the dead
bacteria and five for the live, i.e. 12 of 14 conditions (Table 1). The
effect of combined inhibition was generally greater on the responses to
dead E. coli than for live E. coli.
S. aureus. PMX53 alone reduced the total phagocytosis for both cell
types in response to both live and dead S. aureus (Table 2). Of the five
cytokines measured, three were reduced by PMX53 (IL-1β, TNF and IL-
8) (Table 2). Single CD14 inhibition did not reduce phagocytosis.
However, IL-8 levels were reduced by CD14 inhibition. Note in parti-
cular that IFN-β release in response to S. aureus was not reduced by
CD14 inhibition. In contrast to the marked inhibition seen for E. coli,
IFN-β levels tended to increase in response to S. aureus when CD14 was
inhibited. Notably, when combining PMX53 and anti-CD14, INF-β le-
vels were the only ones unaffected. Thus 12 of 14 cases were sub-
stantially reduced (Table 2). The effect of the combined inhibition was
similar for the responses to dead and live S. aureus.
3.9. Temporal cytokine release in response to E. coli and S. aureus
E. coli induced increased levels of IL-1β, IL-6, IL-8, TNF and IFN-β
for both live and dead bacteria at 120min. In contrast to single in-
hibition, combined inhibition with PMX53 and anti-CD14 attenuated
the release of all cytokines except TNF at 120min (Suppl. Figs. 2–5).
S. aureus induced increased levels of IL-1β, IL-6, IL-8, TNF and INF-β
at 120min. In contrast to single inhibition, combined inhibition with
PMX53 and anti-CD14 attenuated the release of all cytokines at 120min
except IFN-β for live bacteria (Suppl. Figs. 6–8).
Fig. 4. Effects of C5a receptor 1 (C5aR1) blockade and CD14 inhibition on the monocyte phagocytosis of live and dead S. aureus.
The relative inhibition of the phagocytosis of dead (top panels) and live (bottom panels) S. aureus when using the C5aR1 antagonist PMX53 (labelled PMX), a
neutralizing anti-CD14 antibody (labelled aCD14) or the combination thereof (PMX+aCD14) was analyzed at 15, 45, 90 and 120min. * P < 0.05, analyzed using
repeated measures, two-way ANOVA with Dunnet’s multiple comparisons post-hoc test, comparing all columns with the second reference column in black.
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4. Discussion
In this study, we reveal a crucial dependence on the C5a-C5aR1-
axis, with an additional dependence on the Toll-like co-receptor CD14,
for the level of phagocytosis and cytokine release in response to both
live and dead Gram-positive and Gram-negative bacteria in human
whole blood. This corroborates and extends the scope of our previous
work in human whole blood identifying complement and CD14 as key
players in the immediate (10–15min) CD11b expression, phagocytosis
and oxidative burst in response to S. aureus (Skjeflo et al., 2014) and E.
coli in whole blood incubations (Mollnes et al., 2002; Brekke et al.,
2007; Barratt-Due et al., 2010).
As in the aforementioned papers, despite exerting very little effect
on its own, combining CD14 inhibition with central C5a-C5aR1-com-
plement inhibition often potentiated the effect of complement inhibi-
tion alone. This is particularly striking when comparing the effect of
PMX53 to that of PMX53 combined with anti-CD14 in the two tables
summarizing total response in the present paper.
Overall, the responses to both bacteria were largely complement
dependent. However, complement inhibition gradually lost its effect
after 90min and even more so after 120min, particularly on the
monocyte phagocytosis of live bacteria. At this time point, however,
few monocytes were detectable by flow cytometry, probably indicating
that they had disintegrated or somehow succumbed to the bacterial
load. We use 200 monocytes/sample as a minimum to represent the
global monocyte population and we counted 1600 monocytes per
sample on average, of which only two were below 200. Analyses at this
time point therefore had large confidence intervals and low statistical
power. To further examine the reason for these low counts, we con-
ducted experiments with three concentrations of staphylococci
(1× 108/mL, 1×107/mL and 1×106/mL) and assayed both the
effect of complement inhibition and the monocyte counts and viability.
Importantly, complement inhibition had an even greater effect on the
lower concentrations of bacteria, both alone and in combination with
anti-CD14. Interestingly, monocyte numbers were indistinguishable
between the three groups, yet the monocyte death was dose-dependent
on the bacteria. Still, less than 10% of the monocytes counted in flow
cytometry were dead at the highest concentration, suggesting that
monocytes could be disintegrated or bound to the surface of the tubes.
Whether or not phagocyte loss occurs during clinical bacteremia and
sepsis is a fundamental and very interesting question which merits
further testing in the clinical setting.
For the individual cytokines, some notable inter-bacterial differ-
ences were seen, e.g. for inhibition of IFN-β production. E. coli is shown
to mainly induce IFN-β via endosomal or phagosomal TLR4-TRAM-
TRIF-IRF3 activation (Husebye et al., 2010), while S. aureus mainly
induces IFN-β via phagosomal TLR8-IRF5 signaling (Bergstrøm et al.,
2015). E. coli-induced IFN-β production was CD14 dependent, which
fits a model where LPS and TLR4 internalisation are strictly CD14-de-
pendent, resulting in endosomal TLR4 signaling (Jiang et al., 2005;
Zanoni et al., 2011). In comparison, TLR4-NF-kB signaling from the
plasma membrane is only CD14 dependent at low concentrations of LPS
or Gram-negative bacteria (Brekke et al., 2008; Christiansen et al.,
2012). In the present study, a high dose of E. coli was used, which could
explain the relatively weak effect of anti-CD14 on the NF-kB dependent
cytokines. However, we have seen a stronger effect of anti-CD14 on the
cytokine responses induced by E. coli in our previous work (Brekke
et al., 2008). In the case of S. aureus, TLR2-activation blocks TLR8-IRF5
signaling (Bergstrøm et al., 2015) and because TLR2-activation is partly
CD14 dependent (Christiansen et al., 2012) anti-CD14 could lead to
increased IFN-β induction via TLR8.
Unexpectedly, however, with both bacteria we did not reveal a clear
Fig. 5. Effects of C5a receptor 1 (C5aR1) blockade and CD14 inhibition on the granulocyte phagocytosis by different concentrations of live S. aureus.
The inhibition of the phagocytosis in granulocytes of 1×108, 1× 107 and 1×106 staphylococci per mL at 90min (top panels) and 120min (bottom panels) when
using the C5aR1 antagonist PMX53 (PMX), a neutralizing anti-CD14 antibody (aCD14) or the combination thereof (PMX+aCD14). * P < 0.05, analyzed using
repeated measures, two-way ANOVA with Dunnet’s multiple comparisons post-hoc test, comparing all columns with the second reference column in black. All
columns are shown with 95% CI.
E.W. Skjeflo, et al. Molecular Immunology 112 (2019) 131–139
136
correlation with IFN-β production and phagocytosis. This might also be
due to the relatively high dose of bacteria used in this study, as more
than a 50% reduction of phagocytosis might be necessary to limit the
phagosomal signaling. Another possible explanation for the opposing
effects of complement inhibition on the IFN-β response to E. coli in
particular could be that C5a receptor blockade exerted opposing effects.
On the one hand, PMX53 could have increased the IFN-β production by
suppressing the distinct innate cytosolic surveillance pathway described
in a separate study of Listeria monocytogenes (Mueller-Ortiz et al., 2017).
On the other, PMX53 could have reduced the IFN-β production by
reducing the phagocytosis. If so, the combined inhibition of comple-
ment and CD14, which efficiently reduced the phagocytosis of both
bacteria, could explain the reduction of IFN-β as the effect on the
phagocytosis was the most prominent.
Importantly, phagocytosis is both necessary and desirable in sepsis,
especially in localized infection such as in the lung – where staphylo-
cocci readily localize. We argue, however, that reduced phagocytosis
together with adequate antibiotic therapy might be beneficial in sys-
temic inflammation and sepsis. A particular advantage of using PMX53
is that C3 opsonization remains unaltered. Arguably, bacteria are then
Fig. 6. Effects of C5a receptor 1 (C5aR1) blockade and CD14 inhibition on the monocyte phagocytosis by different concentrations of live S. aureus.
The inhibition of the phagocytosis in monocytes of 1×108, 1× 107 and 1× 106 staphylococci per mL at 90min (top panels) and 120min (bottom panels) when
using the C5aR1 antagonist PMX53 (PMX), a neutralizing anti-CD14 antibody (aCD14) or the combination thereof (PMX+aCD14). * P < 0.05, analyzed using
repeated measures, two-way ANOVA with Dunnet’s multiple comparisons post-hoc test, comparing all columns with the second reference column in black. All
columns are shown with 95% CI.
Table 1
Percentage reduction of E. coli-induced inflammatory markers by PMX53, anti-







E. coli viability Live Dead Live Dead Live Dead
Granulocyte
phagocytosis
43*,1 54* 31* 50* 66* 80*
Monocyte
phagocytosis
31* 43* 7 12 39* 70*
IL-1β 22 −10 −32 −28 38* 54*
IL-6 −29 −15 20 48* 21 67*
IL-8 43* 47* 1 15 43* 66*
TNF 4 −1 9 23 15 56*
IFN-β −51 −15 67* 78* 70* 85*
1 Data are from six consecutive time-response experiments in whole blood
from six different donors and data are presented as the mean percentage area
under the response-time (120min) curve (AUC) in inhibited blood compared to
uninhibited, stimulated blood.
* p < 0.05, repeated measures one-way ANOVA.
Table 2
Percentage reduction of S. aureus-induced inflammatory markers by PMX53,







S. aureus viability Live Dead Live Dead Live Dead
Granulocyte
phagocytosis
51*,1 64* −3 −3 53* 68*
Monocyte
phagocytosis
36* 48* 13 −5 47* 63*
IL-1β 85* 74* 47 −3 84* 86*
IL-6 23 14 18 37 86* 80*
IL-8 65* 64* 40* 32* 79* 82*
TNF 58* 52* 24 9 68* 77*
IFN-β 29 29 −36 −20 26 43
1 Data are from six consecutive time-response experiments in whole blood
from six different donors and data are presented as the mean percentage area
under the response-time (120min) curve (AUC) in inhibited blood compared to
uninhibited, stimulated blood.
* p < 0.05, repeated measures one-way ANOVA.
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still targeted for a somewhat slower ingestion and will probably be
transferred to the splenic and hepatic phagocytes, bound to erythrocyte
complement receptor 1 (Brekke et al., 2011). Combined inhibition of
C5aR1 and CD14, together with adequate antibiotic coverage, could
then allow for killing and clearance of the bacteria with less collateral
inflammatory damage.
Interestingly, the phagocytosis of S. aureus as a Gram-positive re-
presentative, was consistently more easily attenuated than that of E. coli
as a Gram-negative counterpart, despite adding S. aureus to a final
concentration of 1×108/mL and E. coli to a final concentration of
1× 107/mL. We have previously identified these concentrations as
equi-potent with respect to readouts like ROS and cytokines (un-
published data), so Gram-negative bacteria and lipopolysaccharide
(LPS) are presumably more potent triggers of the innate immune re-
sponse which is thus harder to inhibit. This also fits the findings of
Günther and colleagues who observed a more sustained and reduced
response to S. aureus when compared to the more acute response to E.
coli in experimental bovine mastitis (Günther et al., 2011). Likewise,
Duan et al. showed small inflammatory responses in mice challenged
with S. aureus compared to E. coli over a 7-day observational period
(Duan et al., 2016). Cohen and Opal also ask whether Gram-positive
sepsis differs from Gram-negative sepsis to such an extent that the two
should be investigated separately for possible therapeutic interventions
(Opal and Cohen, 1999). Our current study, however, indicates that
pre-emptive, combined inhibition of innate immunity works for both
subsets. Indeed, combined inhibition of C5 and CD14 inhibition sig-
nificantly reduced inflammatory mediators and improved survival in
two recently published randomized trials of polymicrobial sepsis in
mice and piglets (Skjeflo et al., 2015; Huber-Lang et al., 2014).
The 120-minute window of our whole blood model is an obvious
limitation of the study, as is the lack of circulation and intact en-
dothelium, and organ perfusion. The strength of our whole blood model
addresses some of these limitations, since it enables all inflammatory
systems in blood, both cellular and fluid-phase, to mutually interact.
“Therapeutic” intervention in this model reveals important cross-talk
between these systems, which is not possible when working with iso-
lated cell systems. Still, future studies could very well address the
question of both phagocyte and bacterial viability over time, perhaps
within a longer time-frame using isolated cell systems. Equally, we need
to assess the possible applicability of combined C5aR1 and CD14 in-
hibition in sepsis by conducting larger, in vivo studies to verify the
findings of the data presented here.
4.1. Conclusion
C5aR1 was crucial for phagocytosis-induced inflammation of live
and dead E. coli and S. aureus, which are both clinically relevant bac-
teria. Additionally, however, CD14 contributed to this effect as com-
bined C5aR1 and CD14 inhibition was the most efficient in reducing the
inflammatory response in general.
Acknowledgements
E. W. Skjeflo, D. Christiansen and A. Landsem carried out the ex-
periments. T. Woodruff contributed with key reagents and in the ana-
lysis and presentation of the data. J. Stenvik and T. Espevik analysed
the data and contributed with the interpretation and presentation of the
data. E. W. Nielsen and T. E. Mollnes contributed to the analysis, in-
terpretation and presentation of the data. All authors contributed to the
design of the experiments and both read, edited and approved the final
version of which E. W. Skjeflo wrote the first draft. This study was fi-
nancially supported by The Odd Fellow Foundation, The Simon
Fougner Hartmann Family Fund and the European Community's
Seventh Framework Programme under grant agreement n°602699
(DIREKT). The funders had no role in study design, data collection and
interpretation, or the decision to submit the work for publication. The
authors declare no conflict of interest.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.molimm.2019.03.014.
References
Barratt-Due, A., Thorgersen, E.B., Lindstad, J.K., Pharo, A., Brekke, O.-L., Christiansen,
D., et al., 2010. Selective inhibition of TNF-alpha or IL-1 beta does not affect E. Coli-
induced inflammation in human whole blood. Mol. Immunol. 47 (May (9)),
1774–1782.
Barratt-Due, A., Thorgersen, E.B., Egge, K., Pischke, S., Sokolov, A., Hellerud, B.C., et al.,
2013. Combined inhibition of complement C5 and CD14 markedly attenuates in-
flammation, thrombogenicity, and hemodynamic changes in porcine sepsis. J.
Immunol. 191 (2), 819–827.
Bergstrøm, B., Aune, M.H., Awuh, J.A., Kojen, J.F., Blix, K.J., Ryan, L., et al., 2015. TLR8
senses Staphylococcus aureus RNA in human primary monocytes and macrophages
and induces IFN-β production via a TAK1-IKKβ-IRF5 signaling pathway. J. Immunol.
195 (Aug (3)), 1100–1111.
Beutler, B., 2004. Innate immunity: an overview. Mol. Immunol. 40 (12), 845–859.
Brekke, O.-L.L., Christiansen, D., Fure, H., Fung, M., Mollnes, T.E., 2007. The role of
complement C3 opsonization, C5a receptor, and CD14 in E. Coli-induced up-reg-
ulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxida-
tive burst in human whole blood. J. Leukoc. Biol. 81 (6), 1404–1413.
Brekke, O.L., Christiansen, D., Fure, H., Pharo, A., Fung, M., Riesenfeld, J., et al., 2008.
Combined inhibition of complement and CD14 abolish E. Coli-induced cytokine-,
chemokine- and growth factor-synthesis in human whole blood. Mol. Immunol. 45
(14), 3804–3813.
Brekke, O.-L.L., Hellerud, B.C., Christiansen, D., Fure, H., Castellheim, A., Nielsen, E.W.,
et al., 2011. Neisseria meningitidis and Escherichia coli are protected from leukocyte
phagocytosis by binding to erythrocyte complement receptor 1 in human blood. Mol.
Immunol. 48 (15–16), 2159–2169.
Brown, K.A., Brain, S.D., Pearson, J.D., Edgeworth, J.D., Lewis, S.M., Treacher, D.F.,
2006. Neutrophils in development of multiple organ failure in sepsis. Lancet. 368
(9530), 157–169.
Christiansen, D., Brekke, O.L., Stenvik, J., Lambris, J.D., Espevik, T., Mollnes, T.E., 2012.
Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. Coli bacteria-
induced cytokine responses in human blood. Adv. Exp. Med. Biol. 946, 237–251.
Croker, D.E., Monk, P.N., Halai, R., Kaeslin, G., Schofield, Z., Wu, M.C., et al., 2016.
Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signal-
ling. Immunol. Cell Biol. 94 (Sep (8)), 787–795.
Dellinger, R.P., Levy, M.M., Rhodes, A., Annane, D., Gerlach, H., Opal, S.M., et al., 2013.
Surviving sepsis campaign: international guidelines for management of severe sepsis
and septic shock: 2012. Crit. Care Med. 41 (2), 580–637.
Duan, J., Xie, Y., Yang, J., Luo, Y., Guo, Y., Wang, C., 2016. Variation of circulating
inflammatory mediators in Staphylococcus aureus and Escherichia coli bloodstream
infection. Med Sci Monit Int Med J Exp Clin Res. 22, 161–171.
Günther, J., Esch, K., Poschadel, N., Petzl, W., Zerbe, H., Mitterhuemer, S., et al., 2011.
Comparative kinetics of Escherichia coli- and Staphylococcus aureus-specific acti-
vation of key immune pathways in mammary epithelial cells demonstrates that S.
Aureus elicits a delayed response dominated by interleukin-6 (IL-6) but not by IL-1A
or tumor necrosis factor alpha. Infect. Immun. 79 (2), 695–707.
Hellerud, B.C., Orrem, H.L., Dybwik, K., Pischke, S.E., Baratt-Due, A., Castellheim, A.,
et al., 2017. Combined inhibition of C5 and CD14 efficiently attenuated the in-
flammatory response in a porcine model of meningococcal sepsis. J. Intensive Care
5, 21.
Huber-Lang, M., Barratt-Due, A., Pischke, S.E., Sandanger, Ø, Nilsson, P.H., Nunn, M.A.,
et al., 2014. Double blockade of CD14 and complement C5 abolishes the cytokine
storm and improves morbidity and survival in polymicrobial sepsis in mice. J.
Immunol. 192 (11), 5324–5331.
Husebye, H., Aune, M.H., Stenvik, J., Samstad, E., Skjeldal, F., Halaas, O., et al., 2010.
The Rab11a GTPase controls Toll-like receptor 4-induced activation of interferon
regulatory factor-3 on phagosomes. Immunity. 33 (Oct (4)), 583–596.
Jiang, Z., Georgel, P., Du, X., Shamel, L., Sovath, S., Mudd, S., et al., 2005. CD14 is
required for MyD88-independent LPS signaling. Nat. Immunol. 6 (Jun (6)), 565–570.
Lau, C., Gunnarsen, K.S., Høydahl, L.S., Andersen, J.T., Berntzen, G., Pharo, A., et al.,
2013. Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in
pig and human models of inflammation. J. Immunol. 1 (Nov (9)), 4769–4777.
Matthews, J.N., Altman, D.G., Campbell, M.J., Royston, P., 1990. Analysis of serial
measurements in medical research. BMJ. 300 (6719), 230–235.
Matzinger, P., 2002. The danger model: a renewed sense of self. Science. 296 (Apr
(5566)), 301–305.
Medzhitov, R., 2008. Origin and physiological roles of inflammation. Nature. 454 (7203),
428–435.
Mollnes, T.E., Brekke, O.-L.L., Fung, M., Fure, H., Christiansen, D., Bergseth, G., et al.,
2002. Essential role of the C5a receptor in E coli-induced oxidative burst and pha-
gocytosis revealed by a novel lepirudin-based human whole blood model of in-
flammation. Blood. 100 (5), 1869–1877.
Mollnes, T.E., Christiansen, D., Brekke, O.L., Espevik, T., 2008. Hypothesis: combined
inhibition of complement and CD14 as treatment regimen to attenuate the in-
flammatory response. Adv. Exp. Med. Biol. 632, 253–263.
E.W. Skjeflo, et al. Molecular Immunology 112 (2019) 131–139
138
Mueller-Ortiz, S.L., Calame, D.G., Shenoi, N., Li, Y.-D., Wetsel, R.A., 2017. The comple-
ment anaphylatoxins C5a and C3a suppress IFN-β production in response to Listeria
monocytogenes by inhibition of the cyclic dinucleotide–Activated cytosolic surveil-
lance pathway. J. Immunol. 198 (Apr (8)), 3237–3244.
Opal, S.M., Cohen, J., 1999. Clinical gram-positive sepsis: does it fundamentally differ
from gram-negative bacterial sepsis? Crit. Care Med. 27 (8), 1608–1616.
Skjeflo, E.W., Christiansen, D., Espevik, T., Nielsen, E.W., Mollnes, T.E., 2014. Combined
inhibition of complement and CD14 efficiently attenuated the inflammatory response
induced by Staphylococcus aureus in a human whole blood model. J. Immunol. 192
(6), 2857–2864.
Skjeflo, E.W., Sagatun, C., Dybwik, K., Aam, S., Urving, S.H., Nunn, M.A., et al., 2015.
Combined inhibition of complement and CD14 improved outcome in porcine poly-
microbial sepsis. Crit. Care 19 (Nov (1)), 415.
Ward, P.A., Gao, H., 2009. Sepsis, complement and the dysregulated inflammatory re-
sponse. J. Cell. Mol. Med. 13 (10), 4154–4160.
Zanoni, I., Ostuni, R., Marek, L.R., Barresi, S., Barbalat, R., Barton, G.M., et al., 2011.
CD14 controls the LPS-Induced endocytosis of toll-like receptor 4. Cell. 147 (Nov (4)),
868–880.
Glossary
C5a: Complement protein 5 fragment a
C5aR1: C5a receptor 1 (CD88)
IFN: Interferon
IL: Interleukin
IRF: Interferon regulatory factor
LPS: Lipopolysaccharide
NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells
PAMPs: Pathogen associated molecular pattern
PBS: Phosphate-buffered saline
TLR: Toll-like receptor
TNF: Tumor necrosis factor
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